Current Therapeutic Limitation
ImmunePrepTM is a development-stage commercialization platform for antibody-based immunotherapies and their corresponding biosimilars. The platform allows for the creation of therapeutic device candidates to enhance the delivery of market-approved or clinical-stage monoclonal antibodies.
“Selective Elimination of Antibody Decoys”
More specifically, ImmunePrepTM allows for a monoclonal antibody to be the active component of an adjunct device that eliminates circulating decoys that would subsequently block the targeted delivery of the same antibody. The dual-use of the same antibody insures the selective elimination of circulating molecules with the structural capability to interfere with mAb delivery. The goal of this reverse-decoy mechanism is to optimize the availability of mAbs to interact with their therapeutic targets. Concurrently, the ability of therapeutic targets to escape antibody interactions would be diminished. Thus, countering a mechanism associated with drug resistance.
“Informative Biomarker Collection from the Entire Circulatory System”
In many cases, circulating targets captured by an ImmunePrepTM device may also be critically informative biomarkers of disease progression and drug resistance. These biomarkers can be eluted from the device post-treatment for laboratory analysis. Additionally, the quantification of therapeutic targets captured within an ImmunePrepTM device and no longer circulating in a recipient patient establishes a datapoint to reinforce treatment performance.
“A Strategy to Deploy Market-Approved or Clinical-Stage Antibodies”
If demonstrated to be clinically effective, ImmunePrepTM products would overcome a therapeutic limitation in healthcare and likely provide a competitive advantage to organizations focused on the commercialization of therapeutic antibodies.
ImmunePrepTM is associated with a provisional patent submission entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” that has been filed with the United States Patent and Trademark Office (“USPTO”).